Galantamine Improves Cognition in Schizophrenic Patients Stabilized on Risperidone

Biological Psychiatry

Volumn 60, Issue 6, 2006, Pages 530-533

  Schubert, Max H ^a   Young, Keith A ^a   Hicks, Paul B ^a  

^a TEXAS A M COLLEGE OF MEDICINE   (United States)

Author keywords

antipsychotic; attention; cholinesterase inhibitor; drug trial; Memory; neuropsychology

Indexed keywords

CHOLINESTERASE INHIBITOR; GALANTAMINE; NEUROLEPTIC AGENT; PLACEBO; RISPERIDONE;

ADD ON THERAPY; ADULT; ARTICLE; ATTENTION; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; EXTRAPYRAMIDAL SYNDROME; FEMALE; HUMAN; MALE; MEMORY; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SYMPTOM; TREATMENT DURATION;

ADULT; ANTIPSYCHOTIC AGENTS; CHOLINESTERASE INHIBITORS; COGNITION; DOUBLE-BLIND METHOD; FEMALE; GALANTAMINE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA;

EID: 33748751285     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2006.04.006     Document Type: Article

References (41)

1. Allen T.B., and McEvoy J.P. Galantamine for treatment-resistant schizophrenia. Am J Psychiatry 159 (2002) 1244-1245
2. Buchanan R.W., Kreyenbuhl J., Zito J.M., and Lehman A. Relationship of the use of adjunctive pharmacological agents to symptoms and level of function in schizophrenia. Am J Psychiatry 159 (2002) 1035-1043
3. Conway M.A., and Dewhurst S.A. Remembering, familiarity, and source monitoring. QJ Exp Psychol A 48 (1995) 125-140
4. Cornblatt B.A., Risch N.J., Faris G., Friedman D., and Erlenmeyer-Kimling L. The Continuous Performance Test, identical pairs version (CPT-IP): I. New findings about sustained attention in normal families. Psychiatry Res 26 (1988) 223-238
5. Cummings J.L. Cholinesterase inhibitors: A new class of psychotropic compounds. Am J Psychiatry 157 (2000) 4-15
6. Danion J.M., Rizzo L., and Bruant A. Functional mechanisms underlying impaired recognition memory and conscious awareness in patients with schizophrenia. Arch Gen Psychiatry 56 (1999) 639-644
7. Friedman J.I., Adler D.N., Howanitz E., Harvey P.D., Brenner G., Temporini H., et al. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry 51 (2002) 349-357
8. Geerts H., Guillaumat P.O., Grantham C., Bode W., Anciaux K., and Sachak S. Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits. Brain Res 1033 (2005) 186-193
9. Gold J.M., Queern C., Iannone V.N., and Buchanan R.W. Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia I: sensitivity, reliability, and validity. Am J Psychiatry 156 (1999) 1944-1950
10. Gold S., Arndt S., Nopoulos P., O'Leary D.S., and Andreasen N.C. Longitudinal study of cognitive function in first-episode and recent-onset schizophrenia. Am J Psychiatry 156 (1999) 1342-1348
11. Goldberg T.E., Ragland J.D., Torrey E.F., Gold J.M., Bigelow L.B., and Weinberger D.R. Neuropsychological assessment of monozygotic twins discordant for schizophrenia. Arch Gen Psychiatry 47 (1990) 1066-1072
12. Goldberg T.E., and Weinberger D.R. Genes and the parsing of cognitive processes. Trends Cogn Sci 8 (2004) 325-335
13. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry 153 (1996) 321-330
14. Green M.F., Kern R.S., Braff D.L., and Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?. Schizophr Bull 26 (2000) 119-136
15. Guy W. Early Clinical Drug Evaluation Unit Assessment Manual (1976), U.S. Department of Health, Education, and Welfare, Rockville, MD
16. Harvey P.D., and Keefe R.S. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 158 (2001) 176-184
17. Hernandez C.M., and Terry Jr. A.V. Repeated nicotine exposure in rats: Effects on memory function, cholinergic markers and nerve growth factor. Neuroscience 130 (2005) 997-1012
18. Howard A.K., Thornton A.E., Altman S., and Honer W.G. Donepezil for memory dysfunction in schizophrenia. J Psychopharmacol 16 (2002) 267-270
19. Joober R., Rouleau G.A., Lal S., Dixon M., O'Driscoll G., Palmour R., et al. Neuropsychological impairments in neuroleptic-responder vs. -nonresponder schizophrenic patients and healthy volunteers. Schizophr Res 53 (2002) 229-238
20. Kay S.R., Opler L.A., and Lindenmayer J.P. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl 7 (1989) 59-67
21. Kihara T., Sawada H., Nakamizo T., Kanki R., Yamashita H., Maelicke A., et al. Galantamine modulates nicotinic receptor and blocks Abeta-enhanced glutamate toxicity. Biochem Biophys Res Commun 325 (2004) 976-982
22. Knapp M.J., Knopman D.S., Solomon P.R., Pendlebury W.W., Davis C.S., Gracon S.I., and The Tacrine Study Group. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 271 (1994) 985-991
23. Lenzi A., Maltinti E., Poggi E., Fabrizio L., and Coli E. Effects of rivastigmine on cognitive function and quality of life in patients with schizophrenia. Clin Neuropharmacol 26 (2003) 317-321
24. Maelicke A., Samochocki M., Jostock R., Fehrenbacher A., Ludwig J., Albuquerque E.X., et al. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol Psychiatry 49 (2001) 279-288
25. Mendelsohn E., Rosenthal M., Bohiri Y., Werber E., Kotle M., and Strous R.D. Rivastigmine augmentation in the management of chronic schizophrenia with comorbid dementia: an open-label study investigating effects on cognition, behaviour and activities of daily living. Int Clin Psychopharmacol 19 (2004) 319-324
26. Morris J.C., Cyrus P.A., Orazem J., Mas J., Bieber F., Ruzicka B.B., et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 50 (1998) 1222-1230
27. Purdon S.E. Cognitive improvement in schizophrenia with novel antipsychotic medications. Schizophr Res 35 Suppl (1999) S51-S60
28. Purdon S.E. Measuring neuropsychological change in schizophrenia with novel antipsychotic medications. J Psychiatry Neurosci 25 (2000) 108-116
29. Purdon S.E., and Flor-Henry P. Asymmetrical olfactory acuity and neuroleptic treatment in schizophrenia. Schizophr Res 44 (2000) 221-232
30. Randolph C., Tierney M.C., Mohr E., and Chase T.N. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 20 (1998) 310-319
31. Raskind M.A., Peskind E.R., Wessel T., Yuan W., and The Galantamine USA-1 Study Group. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 54 (2000) 2261-2268
32. Rockwood K., Mintzer J., Truyen L., Wessel T., and Wilkinson D. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurology, Neurosurgery Psychiatry 71 (2001) 589
33. Rogers S.L., Doody R.S., Mohs R.C., Friedhoff L.T., and Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med 158 (1998) 1021-1031
34. Saint-Cyr J.A., Taylor A.E., and Lang A.E. Procedural learning and neostriatal dysfunction in man. Brain 111 (1988) 941-959
35. Salgado J.V., Vidal M., Oberling P., Graeff F.G., Danion J.M., and Sandner G. Associative learning and latent inhibition in a conditioned suppression paradigm in humans. Behav Brain Res 117 (2000) 53-60
36. Seamans J.K., and Yang C.R. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 74 (2004) 1-58
37. Simpson G.M., and Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212 (1970) 11-19
38. Stryjer R., Strous R.D., Bar F., Werber E., Shaked G., Buhiri Y., et al. Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia. Clin Neuropharmacol 26 (2003) 12-17
39. Van Dam D., Abramowski D., Staufenbiel M., and De Deyn P.P. Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. Psychopharmacology (Berl) 180 (2005) 177-190
40. Weickert T.W., Goldberg T.E., Marenco S., Bigelow L.B., Egan M.F., and Weinberger D.R. Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds. Neuropsychopharmacology 28 (2003) 1491-1500
41. Zhang L., Zhou F.M., and Dani J.A. Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release. Mol Pharmacol 66 (2004) 538-544